New in prevention in blood-transmittedviral hepatitis C
We studied recent data about the effectiveness of different strategies for screening for markers of hepatitis C virus (HCV) in blood donors. Cost-effectiveness of the screening of donated blood is a problem not only for developing but also for developed countries. It involves a thorough assessment of the cost-effectiveness of various technologies. For developed countries there are offered three promising HCV screening strategies: 1) only nucleic acid amplification (NAT) of individual serum for all donors; 2) antibody screening and NAT of minipool of 8 sera for all donors; 3) Only NAT of individual serum - for lapsed and repeat donors; antibody screening and NAT of individual serum - for first-time donors.